Quantity and Quality Controlled Bioprocess of Chimeric Antigen Receptor (CAR)-T Cells
Quantity and Quality Controlled Bioprocess of Chimeric Antigen Receptor (CAR)-T Cells
Targeted indication
Cancer diseases
Status
Non-clinical studies
Key features
- High cell expansion fold: Average 93-188 folds in 6 day-expansion.
- Major cellular immunity populations: Th1 and CTL were major subsets
- Higher cytotoxicity activity and cytokine production: Increase 5-10% of target cell killing and 5-30 ng/mL of IFN-γ production
Market
- In this process, it could reduce the requirement of initial T cell number to 1 to 10 million T cells to perform basic research or clinical treatment.
- Shortening operation time within 10 days and culturing cells at up to4 million cells/mL could lead to the reduction of occupancy of equipment and consumption of materials.
- Control of cell subsets shows the potential of the persistence and potency of CAR-T cells.
MODE OF ACTION
In our process, it could reduce the requirement of initial T cell number to 1 to 10 million T cells to perform basic research or clinical treatment. Shortening operation time within 10 days and culturing cells at up to4 million cells/mL could lead to the reduction of occupancy of equipment and consumption of materials.
EXPERIMENTAL RESULTS
- CAR-T cells expanded to average 188 folds of initial cell number in a 6-day culture in vitro.
- The T cell subsets in this serum-free culture condition were majorly early differentiated Th1 and CTLs.
- The T cell cytotoxicity and cytokine production responding to target cells in DCB’s condition were superior to those in benchmark condition.
NA
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
NA
BUSINESS OPPORTUNITY
License and/or Collaboration
CONTACT
service@biip-dcc.org